|Other Names||Napsin-A, 3423-, Aspartyl protease 4, ASP4, Asp 4, Napsin-1, TA01/TA02, NAPSA, NAP1, NAPA|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13772b was selected from the C-term region of NAPSA. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in processing of pneumocyte surfactant precursors.|
|Tissue Location||Expressed predominantly in adult lung (type II pneumocytes) and kidney and in fetal lung. Low levels in adult spleen and very low levels in peripheral blood leukocytes|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The activation peptides of aspartic proteinases plays roleas inhibitors of the active site. These peptide segments, orpro-parts, are deemed important for correct folding, targeting, andcontrol of the activation of aspartic proteinase zymogens. Thepronapsin A gene is expressed predominantly in lung and kidney. Itstranslation product is predicted to be a fully functional,glycosylated aspartic proteinase precursor containing an RGD motifand an additional 18 residues at its C-terminus. [provided byRefSeq].
Bishop, J.A., et al. Hum. Pathol. 41(1):20-25(2010)Woischnik, M., et al. Eur. Respir. J. 31(6):1197-1204(2008)Ueno, T., et al. Lab. Invest. 88(3):256-263(2008)Innocenti, M., et al. Nat. Cell Biol. 6(4):319-327(2004)Brasch, F., et al. J. Biol. Chem. 278(49):49006-49014(2003)
If you have any additional inquiries please email technical services at email@example.com.